{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-131739","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.763850+00:00","generated_at":"2026-05-15T08:24:02.055867+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"4DMT appoints CFO Kristian Humer as Principal Accounting Officer","bullets":["Appointment effective March 25, 2026; Humer succeeds Ashoo Gupta.","Humer continues as CFO and Principal Financial Officer (role since Nov 2025).","Prior roles include CFO at Foghorn Therapeutics (Apr 2024–Nov 2025) and Viridian Therapeutics.","Gupta remains Vice President, Finance and Controller of the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-131739","json":"https://secwatch.observer/filing/0001193125-26-131739.json","markdown":"https://secwatch.observer/filing/0001193125-26-131739.md","text":"https://secwatch.observer/filing/0001193125-26-131739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526131739/0001193125-26-131739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526131739/fdmt-20260325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:24:02.055867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}